Vinge has advised IK Partners (“IK”) in connection with IK X Fund’s acquisition of SELATEK Holding AB (“Selatek”), a leading Swedish technical installation platform, from Amplio Private Equity AB and the minority shareholders.

Headquartered in Stockholm, Selatek specialises in security, electrical and automation solutions across buildings, infrastructure and industrial environments. The group operates across more than 30 locations in southern and central Sweden, with over 900 full-time employees serving nearly 6,000 customers. Under IK’s ownership, Selatek will continue to pursue organic growth and accelerate its expansion across the Nordics through strategic acquisitions and operational improvements. 

The transaction is subject to customary regulatory approvals.
 
Vinge’s team consisted of Jonas Bergström, Johanna Wiberg, Carl Fredrik Wachtmeister, Sara Hill, Lovisa Jonassen, Hedvig Merkel and Filippa Olsson (M&A), Mario Saad, Katja Häglund and Filippa Eriksson (Commercial Agreements and IT), Niclas Lindblom and Sara Franson (Construction), Simon Söderholm and Louisa Fagarasan (Employment), Wilma Hellman (Real Property and Environment), Axel Lennartsson and Maja Helm (Intellectual Property), Jolinn Uhlin and Olivia Altheden (Banking and Financing), Kateryna Lazarchuk and Vilma Simonius (Compliance), David Olander, Hedvig Josefson, Lovisa Arpi, Hilda Ivarsson, Isak Lefvert and Emil  Bobovac (Competition & Regulatory) and Fanny Askelöf and Caroline Löv (Transaction Support).

Read the client's press release here.

Related

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026